MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for tough lymphoma: experimental pill targets resistant cancer
Disease control OngoingThis study tests an experimental oral drug called rocbrutinib in 62 adults with mantle cell lymphoma whose cancer returned or did not respond to previous treatments. The goal is to see if the drug can shrink tumors. Participants take the drug daily and are monitored for side effe…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated May 26, 2026 06:56 UTC
-
New drug cocktail shows promise against rare blood cancer
Disease control OngoingThis study tests a combination of three drugs (acalabrutinib, venetoclax, and rituximab) in people with untreated mantle cell lymphoma, a rare blood cancer. The goal is to see if the treatment can make the cancer undetectable in the blood and keep it under control. Participants w…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 26, 2026 06:53 UTC
-
New combo therapy shows promise for rare blood cancer
Disease control OngoingThis early-phase study tests a new drug combination for people with untreated mantle cell lymphoma, a rare blood cancer. Participants receive acalabrutinib plus either bendamustine and rituximab or venetoclax and rituximab. The main goal is to check safety and side effects, not t…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE1 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 26, 2026 06:50 UTC
-
New hope for tough lymphoma: targeted drug shows promise in Mid-Stage trial
Disease control OngoingThis phase 2 study tested a drug called acalabrutinib (ACP-196) in 124 adults with mantle cell lymphoma that had returned or stopped responding to prior therapy. The main goal was to see how many patients had their tumors shrink or disappear (overall response rate). The drug is t…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated May 26, 2026 06:43 UTC